InMed Pharmaceuticals: The Clinical-Stage Company Setting Sites On Dominating Rare Cannabinoid Production And Commercialization Across Global Markets

Shane Johnson, SVP and General Manager of Baymedica of InMed Pharmaceuticals INM, was a guest speaker at Benzinga’s All Access on June 17th, 2022. 

InMed Pharmaceuticals is an emerging global leader in the development, manufacturing and commercialization of rare cannabinoids and health and wellness consumer products. 

Watch the full interview here

Feature photo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechCannabisPenny StocksHealth CareMarketsGeneralBenzinga All AccessInMed Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.